Therapeutic potential of the dipeptidyl peptidase IV gene family

二肽基肽酶 IV 基因家族的治疗潜力

• 批准号: nhmrc : 512282
• 负责人: Prof Mark Gorrell
• 金额: $ 31.88万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-potential-dipeptidyl-gene-family/81385
• 关键词: Therapeutic; potential; dipeptidyl; peptidase; IV

We will further investigate the therapeutic potential of the Dipeptidyl Peptidase (DP) IV gene family by studying genes identified as probable therapeutic targets for stem cell transplant, anti-inflammatory and cancer therapies. DPIV is an identified target for diabetes therapy. Our research group is internationally recognised as expert in both liver disease pathogenesis and the DPIV gene family.

我们将进一步研究二肽基肽酶（DP）IV基因家族的治疗潜力，通过研究被确定为干细胞移植，抗炎和癌症治疗的可能治疗靶点的基因。DPIV是糖尿病治疗的确定靶点。我们的研究小组是国际公认的肝病发病机制和DPIV基因家族的专家。